March 5 (Reuters) - Quidel Corp:
* QUIDEL RECEIVES FDA CLEARANCE FOR ITS POINT-OF-CARE SOFIA® LYME FLUORESCENT IMMUNOASSAY FOR USE WITH SOFIA® 2 INSTRUMENT Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.